Evolva SA (SIX: EVE) (Basel, Switzerland) was founded in 2004 around a proprietary technology platform that uses synthetic biology to create innovative small molecule drugs and other high value compounds. Evolva has used this platform across a range of applications and have created novel products and a pipeline of strongly differentiated compounds that address major commercial needs. The most important compounds are: Resveratrol, Vanilla, Pomecin, Stevia and Saffron.

Søren Lemonius, MSc

Managing General Partner

Mobile: +45 40 81 48 89